person · Reporting owner
Gottesdiener Keith Michael
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | Director · See Remarks | May 08, 2025 | May 12, 2025 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Director · CEO & President | March 09, 2020 | March 11, 2020 |
| Septerna, Inc.SEPN · Entity 2452 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.32 · Expires 2034-02-25 | Direct | 300,000 |
Reported balance
After 2025-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 100,000 · Balance 300,000 F1: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares.
RHYTHM PHARMACEUTICALS, INC.
Report date March 09, 2020 · Filed March 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 558,250 |
Reported balance
After 2020-03-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-03-09 · Exercise / conversion · Acquired 3,408 · Balance 558,250 F1: Includes 559 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on March 2, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2027-04-04 | Direct | 207,877 |
Reported balance
After 2020-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-09 · Exercise / conversion · Disposed 3,408 · Balance 207,877 F2: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 559 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on March 2, 2020.
F2: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017.
Septerna, Inc.
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.34 · Expires 2036-06-25 | Direct | 11,260 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 11,260 · Balance 11,260 F1: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 24,719 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 3,196 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2019 Filed Feb 15, 2019 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,934 | $30.00 | $118,020.00 |
DisclosureSEC source: 0001104659-19-009043 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,986 F1 · kind: On February 13, 2019, Mr. Gottesdiener sold 3,934 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 105 | $30.21 | $3,172.05 |
DisclosureSEC source: 0001104659-19-003144 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,920 F3 · kind: On January 23, 2019, Mr. Gottesdiener sold 105 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 15,674 | $30.05 | $471,003.70 |
DisclosureSEC source: 0001104659-19-003144 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,025 F1 · kind: On January 22, 2019, Mr. Gottesdiener sold 15,674 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.63, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 18, 2019 Filed Jan 22, 2019 21:07 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 10,115 | $30.01 | $303,551.15 |
DisclosureSEC source: 0001104659-19-002735 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 560,699 F1 · kind: On January 18, 2019, Mr. Gottesdiener sold 10,115 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.25, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2019 Filed Jan 17, 2019 23:13 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 662 | $30.00 | $19,860.00 |
DisclosureSEC source: 0001104659-19-002328 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,814 F1 · kind: On January 16, 2019, Mr. Gottesdiener sold 662 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.02, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 563 | $30.00 | $16,890.00 |
DisclosureSEC source: 0001104659-18-071680 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,476 F1 · kind: On December 3, 2018, Mr. Gottesdiener sold 563 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 22:21 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 16,500 | $30.08 | $496,320.00 |
DisclosureSEC source: 0001104659-18-066382 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 572,039 F1 · kind: On November 2, 2018, Mr. Gottesdiener sold 16,500 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.28, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,748 | $0.00 Strike: $85.12 | $0.00 |
DisclosureSEC source: 0001144204-18-035417 · tv496984_4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2028-06-20 F2 · derivative.exercise_date: All of the shares subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035417 · tv496984_4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,788 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| May 09, 2018 Filed May 10, 2018 20:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-18-032155 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · C.E.O. and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,780 Underlying: Common Stock · 3,000 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| May 09, 2018 Filed May 10, 2018 20:08 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,000 | $4.59 | $13,770.00 |
DisclosureSEC source: 0001104659-18-032155 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · C.E.O. and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2018 Filed Apr 9, 2018 19:37 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 1,171 | $64.00 | $74,944.00 |
DisclosureSEC source: 0001144204-18-019837 · tv490676_form4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,001 Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:03 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001104659-18-010369 · a4.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-02-13 F1 · derivative.exercise_date: This option was granted on February 14, 2018 and the shares underlying this option vest in sixteen equal quarterly installments. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 20:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionSeries A Convertible Preferred Stock · Derivative | 27,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-061576 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred had no expiration date. F2 · shares: Reflects the number of shares of Series A Preferred held by the Reporting Person on an as-converted to common stock basis. F1 · derivative.exercise_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred had no expiration date. F1 · derivative.expiration_date: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred had no expiration date. F2 · derivative.underlying_shares: Reflects the number of shares of Series A Preferred held by the Reporting Person on an as-converted to common stock basis. Read SEC document |
| October 10, 2017 Filed Oct 10, 2017 20:23 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | ConversionCommon Stock | 27,262 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-061576 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred had no expiration date. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,036 | $0.00 Strike: $122.01 | $0.00 |
DisclosureSEC source: 0001144204-17-035029 · v470069_form4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Common Stock · 2,036 shares Expires 2027-06-27 F1 · derivative.exercise_date: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-035029 · v470069_form4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,830 F1 · shares: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.